Missing Script

Get updates

COUNTRY EXPLORER · SOUTH AMERICA · Researched November 9, 2026

Venezuela offers an unusually instructive intersection of community-held medicinal knowledge, Indigenous healing traditions, cacao cultivation and claims about cancer remedies. This chapter starts with what people have documented using, then asks a separate question: what has actually been tested in people? It covers cancer alongside digestive, respiratory, cardiometabolic, neurologic and inflammatory conditions. No single practice represents all Venezuelans.

Evidence at a glance

  • Cultural documentation, not a clinical trial: a 1991 Warao ethnobotanical investigation documented 100 plant species and 259 preparations, mainly in relation to gastrointestinal conditions; a separate 2024 study in one rural Aragua community documented 116 medicinal species.
  • Strongest controlled non-cancer evidence here: a large U.S. cocoa-flavanol trial had a null primary cardiovascular endpoint; a prespecified/secondary cardiovascular-death signal remains hypothesis-generating. A related analysis found no prevention of type 2 diabetes.
  • Important negative symptom result: two randomized trials of topical aloe gel in people receiving breast/chest-wall irradiation found no protection from radiation dermatitis; they were not conducted in Venezuela.
  • Important safety signals: consumption of Annonaceae plants has been associated with atypical parkinsonism in an observational Caribbean study, while some Jatropha preparations and oral aloe latex/whole-leaf products have toxicologic concerns.
  • Cancer control: no human evidence verified for this chapter establishes that guanábana, the local herbs discussed, cacao, aloe or lemongrass shrinks tumors, reduces recurrence or prolongs survival.

Living knowledge: the Orinoco Delta and rural Aragua

A 1991 original ethnobotanical investigation among Warao practitioners of the Orinoco Delta (Wilbert and Haiek, PMID 1753790; DOI 10.1016/0378-8741(91)90183-E) described 100 species from 45 botanical families, made into 259 formulations for 52 broad classes of complaints. Ten plants used for gastrointestinal disorders underwent phytochemical screening. This was documentation and laboratory characterization, not a randomized treatment study. The original abstract was accessible, but this chapter does not claim to have fully appraised every preparation or the full original ethnography.

A different open-access field study published March 27, 2024 (Monagas and Trujillo; DOI 10.3389/fsufs.2024.1343597) interviewed 41 residents in El Onoto, Valle de Tucutunemo, Aragua. It recorded 116 species used for more than 50 types of health complaints. The protocol initially calculated a 34-person sample, whereas results report 41 respondents; these are not interchangeable numbers. Frequent reports included oregano orejón (Coleus/Plectranthus amboinicus), malojillo (Cymbopogon citratus), tua (Jatropha gossypiifolia) and other locally named plants. Conditions named by participants included cough and flu, stomach symptoms, diabetes, arthritis, cancer and hypertension. Those are reported reasons for use, not verified successful treatments.

The two investigations involve different peoples, places, time periods and research methods. They cannot establish national prevalence or prove that any community is culturally uniform. The source communities are the knowledge holders; appropriate research should involve local stewardship, proper consent, species verification and fair attribution, rather than treating reported remedies as an open catalogue for commercial use.

Respiratory and digestive complaints: malojillo and other infusions

In the Aragua survey, malojillo (Cymbopogon citratus, lemongrass) appeared frequently for gastrointestinal and respiratory complaints. Oregano orejón was also frequently reported for conditions including cough or asthma. These observations say what people reported preparing; they do not measure lung function, asthma attacks, antibiotic need or chronic-disease control.

An original 1986 human study from Brazil (Leite et al.; PMID 2429120; DOI 10.1016/0378-8741(86)90074-7) tested a dried-leaf lemongrass infusion, locally called abafado. In a double-blind comparison involving 50 volunteers, sleep induction and sleep-quality measures did not improve against placebo. In a short safety assessment, routine laboratory measures were generally reassuring, but some people had slight increases in direct bilirubin or amylase without symptoms. The intervention, duration and populations do not establish safety during chemotherapy, chronic liver/kidney disease or pregnancy. The original abstract was accessible, not a complete individual-participant safety dataset.

For asthma, chronic obstructive lung disease or immunosuppressed patients, uncontrolled symptoms cannot safely be managed with infusions alone. Fever or new breathlessness during cancer treatment needs timely assessment rather than a presumed harmless plant remedy.

Cacao: a culturally important food, not a proven preventive medicine

Venezuela has an important history of cacao cultivation, including the living agricultural landscape of Chuao described in UNESCO’s World Heritage tentative-list documentation. Fermented cacao beans and chocolate foods differ markedly from a purified flavanol supplement. Cultural food history does not equal proof that a particular cocoa preparation prevents cancer or heart disease.

A large trial with a negative primary result

The U.S. COSMOS randomized double-blind trial (2022; PMID 35294962; DOI 10.1093/ajcn/nqac055; NCT02422745) randomized 21,442 older adults to cocoa extract (500 mg cocoa flavanols per day, including 80 mg epicatechin), placebo and factorial multivitamin assignments. Over a median 3.6 years, confirmed total cardiovascular events occurred in 410 cocoa-extract participants versus 456 placebo participants; the primary comparison was not statistically significant (HR 0.90, 95% CI 0.78–1.02; P=0.11). A secondary cardiovascular-death analysis favored cocoa extract (HR 0.73, 95% CI 0.54–0.98), but secondary outcomes, multiplicity and subsequent confirmation matter. It is not proof of fewer heart attacks or strokes, and it does not justify any patient dose.

A 2023 COSMOS diabetes analysis (PMID 37816167, same parent trial, not an independent second RCT) included 18,381 adults without diabetes and found no reduction in self-reported new type 2 diabetes over a median 3.5 years: HR 1.04 (95% CI 0.91–1.20); 801 new cases. The original article is publicly available and reports industry-related investigator grants/conflicts; this is important context rather than a reason to discard the randomized results.

COSMOS was conducted in the United States, not Venezuela. Those standardized capsules cannot be equated with sweetened chocolate, raw cacao, culinary use or unspecified local extracts. In the cocoa arm, a cancer secondary-outcome analysis did not establish reduction in total invasive cancer; the trial was not cancer treatment and did not measure tumor response in patients with active malignancy.

Cancer claims: guanábana and the preclinical trap

Guanábana (Annona muricata, soursop/graviola) appears in cancer-related natural-product claims. Laboratory studies of annonaceous acetogenins describe effects on cellular energy pathways and cancer cell lines. These are preclinical signals: they do not measure tumor response, recurrence, survival or safety in patients. A separate Evidence Explorer record on soursop leaf extract and colorectal cancer examines the formulation-specific human-evidence gap. Nothing checked for this chapter establishes guanábana as an effective cancer therapy.

Why safety cannot be ignored: an original 1999 Guadeloupe case-control investigation (PMID 10440304; DOI 10.1016/S0140-6736(98)10166-6) explored the association between consumption of Annonaceae fruits/herbal teas and atypical parkinsonian disorders. It was observational, conducted outside Venezuela and susceptible to confounding and exposure uncertainty; it cannot prove that any given serving of fruit or extract causes Parkinson disease. Nevertheless, mitochondrial/neurotoxicity concerns make concentrated leaf extracts inappropriate to present as risk-free. A 2020 safety review summarized a heterogeneous mixture of in-vitro, animal and limited human information; a favorable review conclusion must not be misread as a large, long-term human safety trial.

Other cancer-support claims: aloe is formulation-specific

Aloe products illustrate why route and preparation matter. A 1996 pair of phase III randomized breast/chest-wall radiation studies (PMID 8892458; DOI 10.1016/S0360-3016(96)00320-3) compared aloe gel with placebo gel in 194 women and with no treatment in 108 patients. The investigator- and patient-scored radiation dermatitis outcomes were essentially the same: the tested topical aloe did not prevent radiodermatitis. Rare contact dermatitis was reported. These were not Venezuelan trials, and the result does not prove all topical preparations are identical.

NCCIH’s aloe safety summary distinguishes topical inner-leaf gel from oral latex and non-decolorized whole-leaf extract. Oral latex can cause cramping and diarrhea, and whole-leaf extracts have been linked to hepatitis reports; non-decolorized whole-leaf extract was classified by IARC as possibly carcinogenic to humans on the available evidence. The hazard classification does not mean topical purified gel is established to cause cancer. An ingredient labeled simply “aloe” is not enough to evaluate safety.

A high-risk plant documented in the Aragua survey

Tua (Jatropha gossypiifolia) was another plant recorded among respondents in the 2024 Aragua survey. A 2014 toxicology review describes caustic latex, dangerous seeds and animal findings of liver, lung, renal and neurologic injury under particular extract/dose conditions. The specific danger depends on part, route and preparation; a short negative toxicity test cannot erase a concerning longer-term animal experiment. This is not a recommendation to prepare or ingest Jatropha. No verified human evidence establishes that it treats cancer, diabetes or autoimmunity.

What about neurologic and autoimmune conditions?

For neurologic health, the most consequential finding in this selection is the possible harm association involving Annonaceae consumption and atypical parkinsonism, not an established cognitive benefit. For autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease or lupus, the selected Venezuelan ethnobotanical reports and related laboratory experiments do not establish disease modification in humans. Anti-inflammatory biomarkers cannot substitute for validated symptoms, organ protection, disability, relapse or medication-sparing outcomes. People taking immunosuppressants or cancer drugs should discuss concentrated extracts with their care team rather than assuming a natural product cannot interact.

Safety map for patients and care teams

  • Identify the exact plant: vernacular names can refer to different species; record Latin name, plant part, form, concentration and supplier.
  • Oncology: do not substitute guanábana or any infused or injected plant product for evidence-based cancer therapy. Check for interactions before chemotherapy, targeted therapy, immunotherapy or surgery. Safety data are often missing, not proof of absence of harm.
  • Neurologic: prolonged or concentrated Annonaceae exposure merits caution given observational and experimental neurotoxicity signals; any new movement disorder needs evaluation.
  • Liver and kidney: distinguish topical from oral aloe; consider Jatropha toxicity, contaminants, hepatotoxicity and the possibility of unverified herbal ingredients.
  • Respiratory or cardiovascular: plants used for cough or blood pressure have not shown that they replace asthma, COPD, hypertension, diabetes or cardiovascular prevention treatment.
  • Pregnancy and children: missing species-specific reproductive and pediatric evidence should not be filled by claims that a traditional use is automatically safe.

Questions worth asking

What is the exact plant and preparation? Which community’s use is being documented, and were those knowledge holders consulted? Did a human study test the same formulation, clinical condition and dose? Was there a placebo or active control? Which outcomes were clinical, which were biomarkers, and what was negative? What is known about adverse events, long-term exposure and interactions with the person’s medicines?

Primary sources and scope of verification

Sources checked November 9, 2026. This is a selective, transparent country chapter rather than a systematic review. It includes historical human research from outside Venezuela where relevant, labeled accordingly. No local randomized human cancer-treatment efficacy study was verified for the selected plants. Missing long-term safety data and unavailable full text are not treated as reassuring negatives. Educational information, not individualized medical advice.